Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-center, Open-label Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Brief Summary: The objective of this study is to evaluate the safety and efficacy of ASP1517 in peritoneal dialysis chronic kidney disease patients with anemia.


Options:
A: Arm Label: AKB-6548; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ASP1517 Low Dose Group (ESA Untreated); Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High Dose Group (ESA Untreated); Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 ESAs Treated Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 ESAs Treated Group, ASP1517 High Dose Group (ESA Untreated), ASP1517 Low Dose Group (ESA Untreated)
C: Arm Label: rhEPO+57Fe followed by Daprodustat+58Fe; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: rhEPO, Drug: Ferrous sulfate containing the stable iron isotope (57Fe), Drug: Ferrous sulfate containing the stable iron isotope (58Fe) | Arm Label: rhEPO+58Fe followed by Daprodustat+57Fe; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: rhEPO, Drug: Ferrous sulfate containing the stable iron isotope (57Fe), Drug: Ferrous sulfate containing the stable iron isotope (58Fe) | Arm Label: Daprodustat+57Fe followed by rhEPO+58Fe; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: rhEPO, Drug: Ferrous sulfate containing the stable iron isotope (57Fe), Drug: Ferrous sulfate containing the stable iron isotope (58Fe) | Arm Label: Daprodustat+58Fe followed by rhEPO+57Fe; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: rhEPO, Drug: Ferrous sulfate containing the stable iron isotope (57Fe), Drug: Ferrous sulfate containing the stable iron isotope (58Fe) | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat+57Fe followed by rhEPO+58Fe, Daprodustat+58Fe followed by rhEPO+57Fe, rhEPO+57Fe followed by Daprodustat+58Fe, rhEPO+58Fe followed by Daprodustat+57Fe | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Daprodustat+57Fe followed by rhEPO+58Fe, Daprodustat+58Fe followed by rhEPO+57Fe, rhEPO+57Fe followed by Daprodustat+58Fe, rhEPO+58Fe followed by Daprodustat+57Fe | Intervention Type: DRUG; Name: Ferrous sulfate containing the stable iron isotope (57Fe); Assigned to Arm(s): Daprodustat+57Fe followed by rhEPO+58Fe, Daprodustat+58Fe followed by rhEPO+57Fe, rhEPO+57Fe followed by Daprodustat+58Fe, rhEPO+58Fe followed by Daprodustat+57Fe | Intervention Type: DRUG; Name: Ferrous sulfate containing the stable iron isotope (58Fe); Assigned to Arm(s): Daprodustat+57Fe followed by rhEPO+58Fe, Daprodustat+58Fe followed by rhEPO+57Fe, rhEPO+57Fe followed by Daprodustat+58Fe, rhEPO+58Fe followed by Daprodustat+57Fe
D: Arm Label: GSK1278863 4 milligrams (mg); Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 4 milligrams (mg), GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B